Form 8-K

8-K — Genprex, Inc.

Accession: 0001437749-26-012879

Filed: 2026-04-21

Period: 2026-04-21

CIK: 0001595248

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — gnpx20260329_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (ex_947990.htm)

GRAPHIC (slide_page01.jpg)

GRAPHIC (slide_page02.jpg)

GRAPHIC (slide_page03.jpg)

GRAPHIC (slide_page04.jpg)

GRAPHIC (slide_page05.jpg)

GRAPHIC (slide_page06.jpg)

GRAPHIC (slide_page07.jpg)

GRAPHIC (slide_page08.jpg)

GRAPHIC (slide_page09.jpg)

GRAPHIC (slide_page10.jpg)

GRAPHIC (slide_page11.jpg)

GRAPHIC (slide_page12.jpg)

GRAPHIC (slide_page13.jpg)

GRAPHIC (slide_page14.jpg)

GRAPHIC (slide_page15.jpg)

GRAPHIC (slide_page16.jpg)

GRAPHIC (slide_page17.jpg)

GRAPHIC (slide_page18.jpg)

GRAPHIC (slide_page19.jpg)

GRAPHIC (slide_page20.jpg)

GRAPHIC (slide_page21.jpg)

GRAPHIC (slide_page22.jpg)

GRAPHIC (slide_page23.jpg)

GRAPHIC (slide_page24.jpg)

GRAPHIC (slide_page25.jpg)

GRAPHIC (slide_page26.jpg)

GRAPHIC (slide_page27.jpg)

GRAPHIC (slide_page28.jpg)

GRAPHIC (slide_page29.jpg)

GRAPHIC (slide_page30.jpg)

GRAPHIC (slide_page31.jpg)

GRAPHIC (slide_page32.jpg)

GRAPHIC (slide_page33.jpg)

GRAPHIC (slide_page34.jpg)

GRAPHIC (slide_page35.jpg)

GRAPHIC (slide_page36.jpg)

GRAPHIC (slide_page37.jpg)

GRAPHIC (slide_page38.jpg)

GRAPHIC (slide_page39.jpg)

GRAPHIC (slide_page40.jpg)

GRAPHIC (slide_page41.jpg)

GRAPHIC (slide_page42.jpg)

GRAPHIC (slide_page43.jpg)

GRAPHIC (slide_page44.jpg)

GRAPHIC (slide_page45.jpg)

GRAPHIC (slide_page46.jpg)

GRAPHIC (slide_page47.jpg)

GRAPHIC (slide_page48.jpg)

GRAPHIC (slide_page49.jpg)

GRAPHIC (slide_page50.jpg)

GRAPHIC (slide_page51.jpg)

GRAPHIC (slide_page52.jpg)

GRAPHIC (slide_page53.jpg)

GRAPHIC (slide_page54.jpg)

GRAPHIC (slide_page55.jpg)

GRAPHIC (slide_page56.jpg)

GRAPHIC (slide_page57.jpg)

GRAPHIC (slide_page58.jpg)

GRAPHIC (slide_page59.jpg)

GRAPHIC (slide_page60.jpg)

GRAPHIC (slide_page61.jpg)

GRAPHIC (slide_page62.jpg)

GRAPHIC (slide_page63.jpg)

GRAPHIC (slide_page64.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: gnpx20260329_8k.htm · Sequence: 1

gnpx20260329_8k.htm

false

0001595248

2026-04-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

April 21, 2026

Date of report (Date of earliest event reported)

GENPREX, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-38244

90-0772347

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(I.R.S. Employer

Identification Number)

3300 Bee Cave Road, #650-227, Austin, TX

78746

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (512) 537-7997

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

GNPX

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Corporate Presentation

The investor presentation about Genprex, Inc. (“Genprex” or the “Company”) that is furnished as Exhibit 99.1 to this Current Report on Form 8-K may be presented at meetings with investors, analysts, and others, in whole or in part and possibly with modifications, from time to time on or after April 21, 2026. A copy of the investor presentation slides, substantially in the form expected to be used in such presentations and meetings, will be available on the Company’s website, www.genprex.com.

The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by a specific reference in such filing.

Item 8.01 Other Events.

On April 21, 2026, Genprex issued a press release announcing it has entered into a new Sponsored Research Agreement (“SRA”) with The University of Texas MD Anderson Cancer Center (“UT MD Anderson”) to study biomarkers that may predict patient response to Reqorsa® Gene Therapy (quaratusugene ozeplasmid), the Company’s lead drug candidate that is in development for the treatment of non-small cell lung cancer (“NSCLC”) and small cell lung cancer (“SCLC”). Shortly after it was founded, Genprex entered its first SRA with UT MD Anderson in 2010, and the two parties have completed several subsequent SRAs. These efforts demonstrate Genprex’s commitment to innovative cancer treatments and improving outcomes for patients through the continued research and development of its oncology pipeline.

In preclinical studies, research collaborators have identified TROP2 and PTEN as two potential biomarkers that may increase the likelihood of patient response to REQORSA. TROP2 (trophoblast cell-surface antigen 2) is a transmembrane glycoprotein that functions as a cell surface receptor. TROP2 overexpression in adult tissues is a hallmark of many solid tumors, making it a major target for modern cancer therapies. PTEN (phosphatase and tensin homolog) is a tumor suppressor gene that serves as a multi-functional cancer biomarker for risk assessment, diagnosis and treatment planning in a number of cancers. The press release further noted that research with TROP2 and PTEN may provide insights that could refine Genprex’s patient selection strategies for its Acclaim-1 and Acclaim-3 clinical trials and optimize clinical outcomes.

Acclaim-1 is a Phase 1/2 clinical trial that uses a combination of REQORSA and AstraZeneca’s Tagrisso® (osimertinib) in patients with late-stage NSCLC that has activating epidermal growth factor receptor mutations and progression on treatment with Tagrisso or Tagrisso-containing regimens. Genprex is currently enrolling and treating patients in the Phase 2a expansion portion of the Acclaim-1 clinical trial following the successful completion of the Phase 1 dose escalation portion of the study. The Phase 1 portion showed REQORSA was generally well tolerated with no dose limiting toxicities (“DLTs”) despite doubling the starting dose. Importantly, the results showed early signs of efficacy with some patients experiencing prolonged progression free survival (“PFS”) and one patient having a partial response. There were three patients out of the twelve originally enrolled in the Phase 1 dose escalation portion of the study who had prolonged PFS. One patient attained a partial remission after the second course of REQORSA and Tagrisso and has maintained this response through 60 courses of treatment (approximately 42 months), and this patient continues to receive REQORSA and Tagrisso treatment to date.

Acclaim-3 is a Phase 1/2 clinical trial that uses a combination of REQORSA and Genentech, Inc.’s Tecentriq® (atezolizumab) as maintenance therapy for patients with extensive stage SCLC who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Patients are treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. Genprex is currently enrolling and treating patients in the Phase 2 expansion portion of the Acclaim-3 clinical trial following the successful completion of the Phase 1 dose escalation portion of the study, which showed no DLTs. One patient in the Phase 1 portion of the study achieved an unconfirmed partial remission after 24 cycles of therapy and continues to receive study treatment in the trial after more than 18 months.

Cautionary Language Concerning Forward-Looking Statements

Statements contained in this Current Report on Form 8-K regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K for the year ended December 31, 2025.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex’s ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines; the timing and success of Genprex’s clinical trials and regulatory approvals; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes, including through research of potential biomarkers that may increase the likelihood of patient response to REQORSA; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex’s diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex’s future growth and financial status, including Genprex’s ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex’s commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; Genprex’s intellectual property and licenses; and Genprex’s current expectations, estimates, forecasts and projections about the industry and markets in which it operates.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this filing. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this filing or to reflect the occurrence of unanticipated events, except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number

Description

99.1

Investor Presentation.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENPREX, INC.

Date: April 21, 2026

By:

/s/ Ryan Confer

Ryan Confer

Chief Executive Officer and Chief Financial Officer

(Principal Executive Officer and Principal Financial and Accounting Officer)

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: ex_947990.htm · Sequence: 2

Image Exhibit

Exhibit 99.1

GRAPHIC

Filename: slide_page01.jpg · Sequence: 7

Binary file (51482 bytes)

Download slide_page01.jpg

GRAPHIC

Filename: slide_page02.jpg · Sequence: 8

Binary file (119974 bytes)

Download slide_page02.jpg

GRAPHIC

Filename: slide_page03.jpg · Sequence: 9

Binary file (40257 bytes)

Download slide_page03.jpg

GRAPHIC

Filename: slide_page04.jpg · Sequence: 10

Binary file (69249 bytes)

Download slide_page04.jpg

GRAPHIC

Filename: slide_page05.jpg · Sequence: 11

Binary file (51789 bytes)

Download slide_page05.jpg

GRAPHIC

Filename: slide_page06.jpg · Sequence: 12

Binary file (34925 bytes)

Download slide_page06.jpg

GRAPHIC

Filename: slide_page07.jpg · Sequence: 13

Binary file (63876 bytes)

Download slide_page07.jpg

GRAPHIC

Filename: slide_page08.jpg · Sequence: 14

Binary file (53861 bytes)

Download slide_page08.jpg

GRAPHIC

Filename: slide_page09.jpg · Sequence: 15

Binary file (51913 bytes)

Download slide_page09.jpg

GRAPHIC

Filename: slide_page10.jpg · Sequence: 16

Binary file (63398 bytes)

Download slide_page10.jpg

GRAPHIC

Filename: slide_page11.jpg · Sequence: 17

Binary file (49136 bytes)

Download slide_page11.jpg

GRAPHIC

Filename: slide_page12.jpg · Sequence: 18

Binary file (45201 bytes)

Download slide_page12.jpg

GRAPHIC

Filename: slide_page13.jpg · Sequence: 19

Binary file (56941 bytes)

Download slide_page13.jpg

GRAPHIC

Filename: slide_page14.jpg · Sequence: 20

Binary file (49327 bytes)

Download slide_page14.jpg

GRAPHIC

Filename: slide_page15.jpg · Sequence: 21

Binary file (46921 bytes)

Download slide_page15.jpg

GRAPHIC

Filename: slide_page16.jpg · Sequence: 22

Binary file (50528 bytes)

Download slide_page16.jpg

GRAPHIC

Filename: slide_page17.jpg · Sequence: 23

Binary file (37623 bytes)

Download slide_page17.jpg

GRAPHIC

Filename: slide_page18.jpg · Sequence: 24

Binary file (52957 bytes)

Download slide_page18.jpg

GRAPHIC

Filename: slide_page19.jpg · Sequence: 25

Binary file (53618 bytes)

Download slide_page19.jpg

GRAPHIC

Filename: slide_page20.jpg · Sequence: 26

Binary file (58342 bytes)

Download slide_page20.jpg

GRAPHIC

Filename: slide_page21.jpg · Sequence: 27

Binary file (69404 bytes)

Download slide_page21.jpg

GRAPHIC

Filename: slide_page22.jpg · Sequence: 28

Binary file (63278 bytes)

Download slide_page22.jpg

GRAPHIC

Filename: slide_page23.jpg · Sequence: 29

Binary file (55136 bytes)

Download slide_page23.jpg

GRAPHIC

Filename: slide_page24.jpg · Sequence: 30

Binary file (68705 bytes)

Download slide_page24.jpg

GRAPHIC

Filename: slide_page25.jpg · Sequence: 31

Binary file (50119 bytes)

Download slide_page25.jpg

GRAPHIC

Filename: slide_page26.jpg · Sequence: 32

Binary file (63755 bytes)

Download slide_page26.jpg

GRAPHIC

Filename: slide_page27.jpg · Sequence: 33

Binary file (37715 bytes)

Download slide_page27.jpg

GRAPHIC

Filename: slide_page28.jpg · Sequence: 34

Binary file (46912 bytes)

Download slide_page28.jpg

GRAPHIC

Filename: slide_page29.jpg · Sequence: 35

Binary file (67916 bytes)

Download slide_page29.jpg

GRAPHIC

Filename: slide_page30.jpg · Sequence: 36

Binary file (63667 bytes)

Download slide_page30.jpg

GRAPHIC

Filename: slide_page31.jpg · Sequence: 37

Binary file (48091 bytes)

Download slide_page31.jpg

GRAPHIC

Filename: slide_page32.jpg · Sequence: 38

Binary file (60815 bytes)

Download slide_page32.jpg

GRAPHIC

Filename: slide_page33.jpg · Sequence: 39

Binary file (71163 bytes)

Download slide_page33.jpg

GRAPHIC

Filename: slide_page34.jpg · Sequence: 40

Binary file (51105 bytes)

Download slide_page34.jpg

GRAPHIC

Filename: slide_page35.jpg · Sequence: 41

Binary file (25679 bytes)

Download slide_page35.jpg

GRAPHIC

Filename: slide_page36.jpg · Sequence: 42

Binary file (47539 bytes)

Download slide_page36.jpg

GRAPHIC

Filename: slide_page37.jpg · Sequence: 43

Binary file (58192 bytes)

Download slide_page37.jpg

GRAPHIC

Filename: slide_page38.jpg · Sequence: 44

Binary file (68659 bytes)

Download slide_page38.jpg

GRAPHIC

Filename: slide_page39.jpg · Sequence: 45

Binary file (66840 bytes)

Download slide_page39.jpg

GRAPHIC

Filename: slide_page40.jpg · Sequence: 46

Binary file (57653 bytes)

Download slide_page40.jpg

GRAPHIC

Filename: slide_page41.jpg · Sequence: 47

Binary file (62420 bytes)

Download slide_page41.jpg

GRAPHIC

Filename: slide_page42.jpg · Sequence: 48

Binary file (47845 bytes)

Download slide_page42.jpg

GRAPHIC

Filename: slide_page43.jpg · Sequence: 49

Binary file (53599 bytes)

Download slide_page43.jpg

GRAPHIC

Filename: slide_page44.jpg · Sequence: 50

Binary file (70074 bytes)

Download slide_page44.jpg

GRAPHIC

Filename: slide_page45.jpg · Sequence: 51

Binary file (58652 bytes)

Download slide_page45.jpg

GRAPHIC

Filename: slide_page46.jpg · Sequence: 52

Binary file (56056 bytes)

Download slide_page46.jpg

GRAPHIC

Filename: slide_page47.jpg · Sequence: 53

Binary file (34176 bytes)

Download slide_page47.jpg

GRAPHIC

Filename: slide_page48.jpg · Sequence: 54

Binary file (51895 bytes)

Download slide_page48.jpg

GRAPHIC

Filename: slide_page49.jpg · Sequence: 55

Binary file (55705 bytes)

Download slide_page49.jpg

GRAPHIC

Filename: slide_page50.jpg · Sequence: 56

Binary file (55793 bytes)

Download slide_page50.jpg

GRAPHIC

Filename: slide_page51.jpg · Sequence: 57

Binary file (26965 bytes)

Download slide_page51.jpg

GRAPHIC

Filename: slide_page52.jpg · Sequence: 58

Binary file (51527 bytes)

Download slide_page52.jpg

GRAPHIC

Filename: slide_page53.jpg · Sequence: 59

Binary file (56944 bytes)

Download slide_page53.jpg

GRAPHIC

Filename: slide_page54.jpg · Sequence: 60

Binary file (38210 bytes)

Download slide_page54.jpg

GRAPHIC

Filename: slide_page55.jpg · Sequence: 61

Binary file (42048 bytes)

Download slide_page55.jpg

GRAPHIC

Filename: slide_page56.jpg · Sequence: 62

Binary file (64403 bytes)

Download slide_page56.jpg

GRAPHIC

Filename: slide_page57.jpg · Sequence: 63

Binary file (51017 bytes)

Download slide_page57.jpg

GRAPHIC

Filename: slide_page58.jpg · Sequence: 64

Binary file (42421 bytes)

Download slide_page58.jpg

GRAPHIC

Filename: slide_page59.jpg · Sequence: 65

Binary file (69828 bytes)

Download slide_page59.jpg

GRAPHIC

Filename: slide_page60.jpg · Sequence: 66

Binary file (59689 bytes)

Download slide_page60.jpg

GRAPHIC

Filename: slide_page61.jpg · Sequence: 67

Binary file (26056 bytes)

Download slide_page61.jpg

GRAPHIC

Filename: slide_page62.jpg · Sequence: 68

Binary file (69703 bytes)

Download slide_page62.jpg

GRAPHIC

Filename: slide_page63.jpg · Sequence: 69

Binary file (54108 bytes)

Download slide_page63.jpg

GRAPHIC

Filename: slide_page64.jpg · Sequence: 70

Binary file (47791 bytes)

Download slide_page64.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 72

v3.26.1

Document And Entity Information

Apr. 21, 2026

Document Information [Line Items]

Entity, Registrant Name

GENPREX, INC.

Document, Type

8-K

Document, Period End Date

Apr. 21, 2026

Entity, Incorporation, State or Country Code

Entity, File Number

001-38244

Entity, Tax Identification Number

90-0772347

Entity, Address, Address Line One

3300 Bee Cave Road

Entity, Address, Address Line Two

#650-227

Entity, Address, City or Town

Austin

Entity, Address, State or Province

Entity, Address, Postal Zip Code

78746

City Area Code

512

Local Phone Number

537-7997

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock

Trading Symbol

GNPX

Security Exchange Name

NASDAQ

Entity, Emerging Growth Company

false

Amendment Flag

false

Entity, Central Index Key

0001595248

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_DocumentInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration